John Eikelboom

Summary

Affiliation: Western Australia
Country: Australia

Publications

  1. ncbi request reprint Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events
    John W Eikelboom
    Department of Medicine, University of Western Australia, Thrombosis and Haemophilia Unit, Royal Perth Hospital, Perth, Australia
    Circulation 105:1650-5. 2002
  2. ncbi request reprint Recombinant activated factor VII for the treatment of life-threatening haemorrhage
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
    Blood Coagul Fibrinolysis 14:713-7. 2003
  3. ncbi request reprint Aspirin resistance: a new independent predictor of vascular events?
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, Wellington Street, Perth, WA 6001, Australia
    J Am Coll Cardiol 41:966-8. 2003
  4. ncbi request reprint The evolving role of direct thrombin inhibitors in acute coronary syndromes
    John Eikelboom
    Department of Medicine, University of Western Australia, Perth, Australia
    J Am Coll Cardiol 41:70S-78S. 2003
  5. ncbi request reprint Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, Box X2213 GPO, Perth, WA 6001, Australia
    Am J Cardiovasc Drugs 4:57-67. 2004
  6. ncbi request reprint Thromboprophylaxis practice patterns in two Western Australian teaching hospitals
    John W Eikelboom
    Department of Hematology, Royal Perth Hospital, Wellington Street, Perth, WA, 6001 Australia
    Haematologica 89:586-93. 2004
  7. ncbi request reprint Low molecular weight heparins and heparinoids
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, GPO Box X2213, Perth, WA 6001, Australia
    Med J Aust 177:379-83. 2002
  8. ncbi request reprint Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials
    Susan Wan
    School of Medicine and Pharmacology, University of Western Australia, Perth, West Australia
    Circulation 110:744-9. 2004
  9. ncbi request reprint Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes
    Paul Cherian
    Department of Medicine, University of Western Australia, Perth, Australia
    Stroke 34:2132-7. 2003
  10. ncbi request reprint Protein Z in ischemic stroke and its etiologic subtypes
    Andrew M McQuillan
    Department of Hematology, Royal Perth Hospital, Box X2213 GPO, Perth, WA 6897, Australia
    Stroke 34:2415-9. 2003

Detail Information

Publications69

  1. ncbi request reprint Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events
    John W Eikelboom
    Department of Medicine, University of Western Australia, Thrombosis and Haemophilia Unit, Royal Perth Hospital, Perth, Australia
    Circulation 105:1650-5. 2002
    ..We studied whether aspirin resistance, defined as failure of suppression of thromboxane generation, increases the risk of cardiovascular events in a high-risk population...
  2. ncbi request reprint Recombinant activated factor VII for the treatment of life-threatening haemorrhage
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
    Blood Coagul Fibrinolysis 14:713-7. 2003
    ..These uncontrolled data suggest a role for rFVIIa as an adjunctive haemostatic measure in surgical patients with life-threatening haemorrhage for whom conventional measures to achieve haemostasis have failed...
  3. ncbi request reprint Aspirin resistance: a new independent predictor of vascular events?
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, Wellington Street, Perth, WA 6001, Australia
    J Am Coll Cardiol 41:966-8. 2003
  4. ncbi request reprint The evolving role of direct thrombin inhibitors in acute coronary syndromes
    John Eikelboom
    Department of Medicine, University of Western Australia, Perth, Australia
    J Am Coll Cardiol 41:70S-78S. 2003
    ..70; 95% confidence interval, 0.56 to 0.87), with little impact on death. Further evaluation of hirudin and bivalirudin in the antithrombotic management of patients with ACS is warranted...
  5. ncbi request reprint Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, Box X2213 GPO, Perth, WA 6001, Australia
    Am J Cardiovasc Drugs 4:57-67. 2004
    ....
  6. ncbi request reprint Thromboprophylaxis practice patterns in two Western Australian teaching hospitals
    John W Eikelboom
    Department of Hematology, Royal Perth Hospital, Wellington Street, Perth, WA, 6001 Australia
    Haematologica 89:586-93. 2004
    ..Our objective was to determine what proportion of patients undergoing elective hip or knee arthroplasty actually receive recommended thromboprophylaxis according to international guidelines...
  7. ncbi request reprint Low molecular weight heparins and heparinoids
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, GPO Box X2213, Perth, WA 6001, Australia
    Med J Aust 177:379-83. 2002
    ..The heparinoid danaparoid sodium is effective for the treatment of heparin-induced thrombocytopenia...
  8. ncbi request reprint Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials
    Susan Wan
    School of Medicine and Pharmacology, University of Western Australia, Perth, West Australia
    Circulation 110:744-9. 2004
    ..Randomized trials and meta-analyses have reached conflicting conclusions about the role of thrombolytic therapy for the treatment of acute pulmonary embolism...
  9. ncbi request reprint Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes
    Paul Cherian
    Department of Medicine, University of Western Australia, Perth, Australia
    Stroke 34:2132-7. 2003
    ..We also hypothesized that these markers would be differentially elevated in ischemic stroke caused by large- and small-artery atherothrombosis compared with cardiogenic embolism...
  10. ncbi request reprint Protein Z in ischemic stroke and its etiologic subtypes
    Andrew M McQuillan
    Department of Hematology, Royal Perth Hospital, Box X2213 GPO, Perth, WA 6897, Australia
    Stroke 34:2415-9. 2003
    ..The objectives of this study were to determine the association between protein Z, ischemic stroke, and etiologic subtypes of ischemic stroke...
  11. ncbi request reprint Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant
    Jim Thom
    Coagulation and Thrombosis Unit, Department of Haematology, Royal Perth Hospital, Perth, Western Australia, Australia
    Blood Coagul Fibrinolysis 15:353-7. 2004
    ..60, P < 0.0001) but there was no correlation in the presence of lupus anticoagulant (r = -0.13, P = 0.68). Our results suggest that the prdRVVT is not suitable for monitoring warfarin therapy in patients with lupus anticoagulant...
  12. ncbi request reprint Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks
    Graeme J Hankey
    Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, Australia
    Neurology 64:1117-21. 2005
    ....
  13. ncbi request reprint Venous thromboembolism in travellers: can we identify those at risk?
    Andrew D McQuillan
    Department of Haematology, Royal Perth Hospital, Perth, Australia, and School of Medicine and Pharmacology, University of Western Australia
    Blood Coagul Fibrinolysis 14:671-5. 2003
    ..Whether patients with known risk factors for venous thromboembolism prior to travel should be targeted with specific thromboprophylaxis requires randomized evaluation...
  14. ncbi request reprint Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?
    John W Eikelboom
    Department of Medicine, Thrombosis and Haemophilia Unit, University of Western Australia, Royal Perth Hospital, Australia
    Drugs 62:1839-52. 2002
    ....
  15. ncbi request reprint Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia
    Julie H Crawford
    Royal Perth Hospital, Perth, Western Australia, Australia
    Eur J Haematol 69:315-7. 2002
    ....
  16. ncbi request reprint Antiplatelet agents in acute coronary syndromes
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital and Department of Medicine, University of Western Australia, Crawley, WA, Australia
    Semin Vasc Med 3:403-14. 2003
    ....
  17. ncbi request reprint Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?
    Wai Khoon Ho
    Centre for Clinical Research Excellence, Department of Neurology and Department of Haematology, Royal Perth Hospital, Australia and School of Medicine and Pharmacology, University of Western Australia, Australia
    Blood Coagul Fibrinolysis 15:129-30. 2004
  18. ncbi request reprint Venous thromboembolism: diagnosis and management of deep venous thrombosis
    Wai Khoon Ho
    Royal Perth Hospital, Perth, WA
    Med J Aust 182:476-81. 2005
    ..The risk of recurrence is highest in people with recurrent unprovoked DVT or chronic predisposing factors (eg, cancer) who require indefinite anticoagulant treatment...
  19. ncbi request reprint Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia
    Susan Wan
    School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia, Australia
    ANZ J Surg 73:826-9. 2003
    ..The purpose of the present study was to examine current thromboprophylaxis practice patterns in patients undergoing hip fracture surgery at Royal Perth Hospital...
  20. ncbi request reprint Venous thromboembolism: diagnosis and management of pulmonary embolism
    Cindy H Lee
    Department of Haematology, Royal Perth Hospital, Perth, WA, Australia
    Med J Aust 182:569-74. 2005
    ....
  21. ncbi request reprint Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review
    Wai Khoon Ho
    Department of Haematology, Royal Perth Hospital and Centre for Clinical Research Excellence, University of Western Australia, Perth
    Arch Intern Med 166:729-36. 2006
    ..These data call into question the cost-effectiveness of routine testing for these common inherited thrombophilic polymorphisms among patients with a first episode of VTE...
  22. ncbi request reprint Clinical usefulness of plasma homocysteine in vascular disease
    Graeme J Hankey
    Department of Neurology, Royal Perth Hospital, Wellington Street, Perth, Western Australia, 6001
    Med J Aust 181:314-8. 2004
    ..There is currently insufficient evidence to recommend routine screening and treatment of high tHcy concentrations with folic acid and other vitamins to prevent atherothrombotic vascular disease...
  23. ncbi request reprint Aspirin resistance
    Graeme J Hankey
    Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia
    Lancet 367:606-17. 2006
    ..Potential mechanisms of aspirin resistance can then be explored and treatments assessed...
  24. doi request reprint Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events
    Graeme J Hankey
    Department of Neurology, Royal Perth Hospital, Australia
    Lancet Neurol 9:273-84. 2010
    ..Other new anticoagulants, including the oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, the parenteral factor Xa inhibitor, idrabiotaparinux, and the novel VKA, tecarfarin, are currently being assessed...
  25. ncbi request reprint The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia
    Wai Khoon Ho
    Department of Haematology, Austin and Repatriation Medical Centre, Melbourne, Vic, Australia
    Med J Aust 189:144-7. 2008
    ....
  26. ncbi request reprint Antiplatelet drugs
    Graeme J Hankey
    Royal Perth Hospital, 197 Wellington Street, Perth, WA 6001, Australia
    Med J Aust 178:568-74. 2003
    ....
  27. pmc The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis
    Kathleen Potter
    School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    BMC Cardiovasc Disord 8:24. 2008
    ..B-vitamin supplements reduce tHcy and improve endothelial function in short term trials, but the long-term effects of the treatment on vascular structure and function are unknown...
  28. ncbi request reprint Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness
    Wai Khoon Ho
    Department of Haematology, Royal Perth Hospital, Perth, Australia
    Expert Opin Pharmacother 5:493-503. 2004
    ..g., > 20%/year). The combination of clopidogrel and aspirin should be considered in patients with non-ST-segment elevation acute coronary syndrome or undergoing percutaneous coronary intervention...
  29. ncbi request reprint Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?
    Graeme J Hankey
    Stroke Unit, Department of Neurology, Royal Perth Hospital, Box X2213 GPO, Perth, WA 6001, Australia
    Stroke 34:2736-40. 2003
    ....
  30. doi request reprint The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality
    Magdalena Sobieraj-Teague
    Department of Haematology, Flinders Medical Centre, Adelaide, Australia
    Curr Opin Cardiol 23:327-34. 2008
    ....
  31. doi request reprint Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin
    Gerald Yong
    Royal Perth Hospital, Perth, Western Australia, Australia
    Am Heart J 157:60.e1-9. 2009
    ..There is uncertainty about the benefit of a higher loading dose (LD) of clopidogrel in patients with non-ST elevation acute coronary syndrome (NSTEACS) undergoing early percutaneous coronary intervention (PCI)...
  32. doi request reprint Homocysteine or renal impairment: which is the real cardiovascular risk factor?
    Kathleen Potter
    Department of Cardiology, Level 4, A Block, Royal Perth Hospital, Perth WA6847, Australia
    Arterioscler Thromb Vasc Biol 28:1158-64. 2008
    ....
  33. ncbi request reprint Suboptimal preventive practices in patients with carotid and peripheral vascular occlusive disease in a tertiary referral setting
    Lip Gen Teh
    Department of Vascular Surgery, Royal Perth Hospital, Perth, Western Australia, Australia
    ANZ J Surg 73:932-7. 2003
    ..This study aims to examine and compare the use of preventive therapy in patients admitted for interventions related to peripheral and carotid atherosclerotic occlusive disease...
  34. ncbi request reprint The tissue factor pathway in ischemic stroke
    Murray J Adams
    Western Australian Biomedical Research Institute, School of Biomedical Sciences, Curtin University, Perth, Australia
    Blood Coagul Fibrinolysis 17:527-32. 2006
    ....
  35. doi request reprint Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial
    Kathleen Potter
    School of Medicine and Pharmacology, University of Western Australia, W A, Australia
    Cerebrovasc Dis 27:259-65. 2009
    ..We used (18)F-fluorodeoxygluose positron emission tomography ((18)F-FDG PET) to investigate whether long-term homocysteine-lowering treatment alters arterial wall inflammation in patients with a history of ischemic stroke...
  36. pmc Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI)
    Huyen Tran
    Department of Clinical Haematology, Monash Medical Centre, Victoria, Australia
    Vasc Health Risk Manag 2:379-87. 2006
    ..Thus, dual antiplatelet therapy with the combination of clopidogrel and aspirin is becoming the new standard of care for the management of patients with STEMI...
  37. ncbi request reprint Aspirin resistance
    Huyen A Tran
    Department of Clinical Haematology, Monash Medical Centre, Clayton, Victoria, Australia
    Thromb Res 120:337-46. 2007
    ....
  38. ncbi request reprint Who is (still) getting HIT?
    Theodore E Warkentin
    Chest 131:1620-2. 2007
  39. pmc Anticoagulation for venous thromboembolism
    John W Eikelboom
    BMJ 334:645. 2007
  40. ncbi request reprint Latest medical treatment strategies for venous thromboembolism
    Simon J McRae
    The Queen Elizabeth Hospital, Institute of Medical and Veterinary Sciences, Department of Haematology Oncology, 28 Woodville Rd, Woodville 5011, Adelaide, South Australia, Australia
    Expert Opin Pharmacother 8:1221-33. 2007
    ....
  41. pmc Inherited thrombophilia and pregnancy associated venous thromboembolism
    Wendy Lim
    Department of Medicine, McMaster University, St Joseph s Hospital, Canada
    BMJ 334:1318-21. 2007
  42. ncbi request reprint Beyond unfractionated heparin and warfarin: current and future advances
    Jack Hirsh
    Henderson Research Centre, Hamilton Health Sciences Corporatin, Ontario, Canada
    Circulation 116:552-60. 2007
  43. ncbi request reprint Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial
    Shamir R Mehta
    Department of Medicine, McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
    J Am Coll Cardiol 50:1742-51. 2007
    ..This study reports a prospectively planned analysis of patients with acute coronary syndrome who underwent early percutaneous coronary intervention (PCI) in the OASIS-5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial...
  44. doi request reprint The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies
    Jack C J Sun
    Division of Cardiac Surgery, Hamilton General Hospital, McMaster University, 237 Barton St E, Hamilton, Ontario, Canada L8L 2X2
    Eur Heart J 29:1057-71. 2008
    ..To obtain estimates of the efficacy and safety of pre-operative aspirin in patients undergoing coronary artery bypass grafting (CABG)...
  45. doi request reprint Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review
    MARTIN J O'DONNELL
    McMaster University, Ontario, Canada
    Stroke 39:1638-46. 2008
    ....
  46. doi request reprint Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk
    John W Eikelboom
    McMaster University, Hamilton, Ontario, Canada
    Circulation 118:1705-12. 2008
    ....
  47. ncbi request reprint Guidelines for the management of acute coronary syndromes 2006
    John W Eikelboom
    Med J Aust 186:101; discussion 101-2. 2007
  48. ncbi request reprint Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes
    James D Douketis
    Department of Medicine, McMaster University, and St Joseph s Hospital, Hamilton, Ontario, Canada L8N 4A6
    Arch Intern Med 162:1465-71. 2002
    ....
  49. ncbi request reprint Aspirin for the primary prevention of cardiovascular events
    Graeme J Hankey
    Med J Aust 177:343-4. 2002
  50. pmc Aspirin resistance
    Graeme J Hankey
    BMJ 328:477-9. 2004
  51. ncbi request reprint Long-term management of venous thromboembolism: is there a role for low-intensity warfarin therapy?
    John W Eikelboom
    Med J Aust 179:68-9. 2003
    ..The recently released PREVENT trial provides some answers...
  52. ncbi request reprint The beginning of the end of warfarin?
    John W Eikelboom
    Med J Aust 180:549-51. 2004
  53. ncbi request reprint Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?
    Graeme J Hankey
    Stroke Unit, Royal Perth Hospital, 197 Wellington Street Perth, Australia 6001
    Stroke 35:389-91. 2004
  54. ncbi request reprint Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events
    Paul E Langton
    Med J Aust 181:524-5. 2004
  55. ncbi request reprint Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes
    Shamir R Mehta
    Department of Medicine, Mc Master University, Hamilton Health Sciences, Hamilton, ON, Canada
    Can J Physiol Pharmacol 83:98-103. 2005
    ..Despite this worse prognosis, patients with ACS developing CHF are less likely to be referred for invasive management...
  56. ncbi request reprint Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials
    Daniel J Quinlan
    King s College Hospital, London, United Kingdom
    Ann Intern Med 140:175-83. 2004
    ..However, for patients who present with pulmonary embolism, the role of low-molecular-weight heparin is uncertain and unfractionated heparin remains widely used...
  57. ncbi request reprint Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials
    John W Eikelboom
    General Division, Hamilton Health Sciences, Hamilton, Ontario, Canada
    Circulation 112:3855-67. 2005
    ..There is uncertainty about the role of intravenous unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in patients with ST-elevation myocardial infarction (STEMI) treated with aspirin and thrombolysis...
  58. ncbi request reprint Editorial comment--Routine thrombophilia testing in stroke patients is unjustified
    Graeme J Hankey
    Stroke 34:1826-7. 2003
  59. ncbi request reprint Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
    Andrew McQuillan
    N Engl J Med 346:1589-90; author reply 1589-90. 2002
  60. ncbi request reprint Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency
    Wendy Lim
    McMaster University and Hamilton General Hospital, Hamilton, Ontario, Canada
    Ann Intern Med 144:673-84. 2006
    ....
  61. ncbi request reprint Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction
    Peter Sleight
    N Engl J Med 354:2830-1; author reply 2831-2. 2006
  62. ncbi request reprint Adverse impact of bleeding on prognosis in patients with acute coronary syndromes
    John W Eikelboom
    Thrombosis Service, Hamilton Health Sciences, Hamilton, Ontario, Canada
    Circulation 114:774-82. 2006
    ..The use of multiple antithrombotic drugs and aggressive invasive strategies has increased the risk of major bleeding in acute coronary syndrome (ACS) patients. It is not known to what extent bleeding determines clinical outcome...
  63. pmc Antithrombotic treatment for peripheral arterial disease
    Daniel G Hackam
    Division of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Canada
    Heart 93:303-8. 2007
    ..In addition, this disorder is associated with a systemic milieu characterised by ongoing platelet activation and heightened thrombogenesis...
  64. ncbi request reprint Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction
    John K French
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Am J Cardiovasc Drugs 4:107-15. 2004
    ..The major benefit of direct thrombin inhibitors appears to be in patients undergoing PCI, particularly after STEMI...
  65. ncbi request reprint Will prasugrel supersede clopidogrel for acute coronary syndromes?
    Graeme J Hankey
    Med J Aust 188:381-2. 2008
  66. ncbi request reprint Monitoring unfractionated heparin with the aPTT: time for a fresh look
    John W Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton Health Sciences Corporation and McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 96:547-52. 2006
    ..However, currently available unfractionated heparin assays are much more expensive than the aPTT, are not widely available, and their validity has not been adequately assessed in clinical outcome studies...
  67. ncbi request reprint Bone marrow biopsy in thrombocytopenic or anticoagulated patients
    John W Eikelboom
    Br J Haematol 129:562-3. 2005
  68. ncbi request reprint Management of antiphospholipid antibody syndrome: a systematic review
    Wendy Lim
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    JAMA 295:1050-7. 2006
    ..Patients with APS may be at increased risk of recurrent arterial or venous thrombosis or pregnancy loss...
  69. ncbi request reprint A replacement for warfarin: the search continues
    John W Eikelboom
    Circulation 116:131-3. 2007